RxDoctor Payments Data

Melissa Lunsford, NP

Family · Raleigh, NCNPI 1336598952

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 73 payments — averaging $39.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$950
  • Teleflex LLC$339
  • Johnson & Johnson$299
  • Sumitomo Pharma America, Inc.$254
  • Bayer$171
  • Pfizer$133
  • plus $712 from 18 others

What the payments were for

  • Travel & lodging$68224%
  • Food & beverage$2,09273%
  • Education$853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,858 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$75,488
Medicare patients
322
Services billed
2,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron23$24,107
Testosterone18$3,305
Tamsulosin Hcl102$1,464
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$1,426
Finasteride62$1,254
Ciprofloxacin Hcl71$713
Alfuzosin Hcl ErAlfuzosin Hcl29$648
Estradiol12$641
Cefdinir29$619
Ondansetron OdtOndansetron57$380
Cephalexin33$274
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$259
Oxybutynin Chloride30$150
Oxycodone Hcl69$133
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim40$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$254$24,10723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.

Other family in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →